financetom
Business
financetom
/
Business
/
Starbucks names Chipotle's Brian Niccol as CEO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Starbucks names Chipotle's Brian Niccol as CEO
Aug 13, 2024 5:52 AM

Aug 13 (Reuters) - Starbucks ( SBUX ) announced on

Tuesday that Brian Niccol has been appointed chairman and chief

executive officer.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
George Weston Q3 Adjusted Earnings Beat Estimates
George Weston Q3 Adjusted Earnings Beat Estimates
Nov 14, 2025
07:31 AM EST, 11/14/2025 (MT Newswires) -- George Weston (WN.TO), which operates through its two operating companies, Loblaw (L.TO) and Choice Properties REIT (CHP-UN.TO), said Friday that third-quarter adjusted earnings beat forecasts, and revenue advanced. Adjusted net earnings rose 12% to $533 million, or $1.37 per diluted share, from $476 million, or $1.19 per diluted share, in the prior year...
BMO on The Day Ahead in Canada
BMO on The Day Ahead in Canada
Nov 14, 2025
07:33 AM EST, 11/14/2025 (MT Newswires) -- Canada will publish manufacturing sales for September at 8:30 a.m. ET on Friday, said Bank of Montreal (BMO). Manufacturing sales are expected to increase 2.8% month over month in September, more than reversing August's decrease, in line with the advance estimate, noted the bank. BMO is also looking for growth in new orders...
Scholar Rock Q3 Net Loss Widens; Shares Up
Scholar Rock Q3 Net Loss Widens; Shares Up
Nov 14, 2025
07:32 AM EST, 11/14/2025 (MT Newswires) -- Scholar Rock ( SRRK ) reported a Q3 net loss Friday of $0.90 per diluted share, widening from its net loss of $0.66 a year earlier. Analysts polled by FactSet expected a net loss of $0.84. The biopharmaceutical company said it had $369.6 million in cash, cash equivalents, and marketable securities as of...
Bristol-Myers Squibb, Johnson & Johnson Stop Phase 3 Trial for Heart Condition
Bristol-Myers Squibb, Johnson & Johnson Stop Phase 3 Trial for Heart Condition
Nov 14, 2025
07:32 AM EST, 11/14/2025 (MT Newswires) -- Bristol-Myers Squibb Company ( BMY ) in collaboration with Johnson & Johnson ( JNJ ) , said Friday that they have stopped a phase 3 trial of their experimental drug, milvexian, added to the standard of care for patients recovering from a recent acute coronary syndrome event. The companies said that the decision...
Copyright 2023-2026 - www.financetom.com All Rights Reserved